2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone has been researched along with methoxydine* in 2 studies
1 review(s) available for 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone and methoxydine
Article | Year |
---|---|
Out with the old, in with the new? Case reports of the clinical features and acute management of two novel designer drugs.
Methoxydine (4-MeO-PCP) and Methoxetamine (3-MeO-2-Oxo-PCE) are both commercially produced designer drugs with structural and biochemical similarities to phencyclidine (PCP). Although phencyclidine toxicity is well documented, its recreational use in present times is rare. With the advent of new designer drugs being available widely through internet sites, Acute Physicians should be aware of the clinical features and management of these potential toxins. We present a case of methoxydine ingestion (which to our knowledge has not been previously documented in any medical journals) and a case of methoxetamine ingestion, and discuss their history, contrasting clinical features and acute management. Topics: Adult; Cyclohexanones; Cyclohexylamines; Designer Drugs; Drug Overdose; Emergency Service, Hospital; Emergency Treatment; Follow-Up Studies; Humans; Illicit Drugs; Incidence; Male; Middle Aged; Neurotoxicity Syndromes; Phencyclidine; Risk Assessment; Substance-Related Disorders; Treatment Outcome | 2012 |
1 other study(ies) available for 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone and methoxydine
Article | Year |
---|---|
Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays.
Methoxetamine (MXE) and the arylcyclohexylamines 3-methoxy-PCP (3-MeO-PCP) and 4-methoxy-PCP (4-MeO-PCP) are substituted analogs of the dissociative psychoactive substances ketamine and phencyclidine (PCP), respectively. They have emerged on the new psychoactive substances (NPS) market as legal alternatives to these classically banned dissociatives. Little data has been published regarding the cross-reactivity of these NPS in PCP immunoassays (IAs). The aim of this work was to explore the possibilities of detecting 3-MeO-PCP, 4-MeO-PCP, MXE and ketamine in commercial IAs for PCP. The cross-reactivity study was performed in five different PCP IAs using urine-free, spiked samples and urine samples obtained from two 3-MeO-PCP overdose cases. 3-MeO-PCP and 4-MeO-PCP showed cross-reactivity (ranging from 1-143%) in all PCP IAs evaluated. MXE only showed very weak cross-reactivity (ranged from 0.04 to 0.25%) and ketamine was not detected in any PCP IA evaluated. Urine samples from the two overdose cases were positive for PCP in all IAs evaluated. The commercial PCP IAs evaluated exhibited utility as rapid, preliminary screening techniques for 3-MeO-PCP and 4-MeO-PCP, but not for ketamine. The low reactivity of MXE limits its detectability in the PCP IAs evaluated. Topics: Body Fluids; Cyclohexanones; Cyclohexylamines; Drug Overdose; Humans; Immunoassay; Ketamine; Phencyclidine; Psychotropic Drugs | 2019 |